Triplet Therapeutics to Present at Stifel Virtual Healthcare Conference
November 16, 2020CAMBRIDGE, Mass.–(BUSINESS WIRE)–Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president, and founder, will present at the Stifel Virtual Healthcare Conference taking place November 16-18, 2020.
Dr. Bermingham will discuss Triplet’s recent activities, including:
- The company’s selection of its first clinical candidate from its proprietary thRED Engine™, TTX-3360, an antisense oligonucleotide with the potential to modify the course of REDs by targeting the DNA Damage Response (DDR) pathway;
- Its recent completion of enrollment in SHIELD HD, an international natural history study of Huntington’s disease; and
- Its participation in END-DM1, a large international natural history study of myotonic dystrophy type 1 (DM1).
Dr. Bermingham’s presentation details are as follows:
Date: Wednesday, November 18
Time: 9:20 a.m. ET
A webcast of the presentation can be viewed on the conference website.
About TTX-3360
TTX-3360, an antisense oligonucleotide, is the first clinical candidate developed from Triplet’s proprietary thRED Engine and the first clinical candidate with the potential to modify the course of repeat expansion disorders (REDs) by targeting the DNA Damage Response (DDR) pathway. (Read more…) A significant body of evidence supports the role of the DDR pathway as the primary driver of repeat expansion and subsequent disease onset and progression in many REDs, including Huntington’s disease (HD), myotonic dystrophy (DM1) and fragile X syndrome. Triplet is initially focusing development of TTX-3360 in HD and may also evaluate it in other central nervous system indications such as spinocerebellar ataxias (SCAs), fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS).
About Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) – a group of more than 50 known genetic diseases including myotonic dystrophy type 1 (DM1), Huntington’s disease (HD), spinocerebellar ataxias (SCAs), fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) – leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs.
Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.
Contacts
Mary Carmichael
Ten Bridge Communications
[email protected]
617-413-3543